Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ra Capital Management, L.P. Sells 101,151 Shares

Posted by Stanley Muller on May 13th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ra Capital Management, L.P. sold 101,151 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $0.64, for a total transaction of $64,736.64. Following the sale, the insider directly owned 406,282 shares in the company, valued at approximately $260,020.48. This trade represents a 19.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $58,618.30.
On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Trading Down 4.3%

Shares of NASDAQ:HOWL opened at $0.63 on Wednesday. The stock has a market capitalization of $30.72 million, a PE ratio of -0.51 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 1 year low of $0.53 and a 1 year high of $2.38. The firm has a fifty day moving average price of $0.81 and a 200 day moving average price of $0.83.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. On average, sell-side analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Regal Investment Advisors LLC boosted its holdings in Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares during the period. Vontobel Holding Ltd. boosted its holdings in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after acquiring an additional 24,003 shares during the period. Renaissance Technologies LLC boosted its holdings in Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after acquiring an additional 221,766 shares during the period. Susquehanna International Group LLP boosted its holdings in Werewolf Therapeutics by 16.9% during the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after acquiring an additional 13,439 shares during the period. Finally, Citadel Advisors LLC bought a new stake in shares of Werewolf Therapeutics in the third quarter valued at about $304,000. 64.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $3.75.

View Our Latest Stock Analysis on Werewolf Therapeutics

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.